Price to FCFE (P/FCFE)

Free Cash Flow to Equity (FCFE)
P to FCFE Ratio, Current
P to FCFE Ratio, Historical

Paying user area

Try for free

Boston Scientific Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get full access to the entire website from $10.42/mo, or
get 1-month access to Boston Scientific Corp. for $22.49.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Free Cash Flow to Equity (FCFE)

Boston Scientific Corp., FCFE calculation

US$ in millions

	12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
	Net income (loss)
	Net noncash charges
	Increase (decrease) in operating assets and liabilities, excluding purchase accounting
	Cash provided by operating activities
	Purchases of property, plant and equipment and internal use software
	Proceeds from sale of property, plant and equipment
	Payments on short-term borrowings
	Proceeds from short-term borrowings, net of debt issuance costs
	Net increase (decrease) in commercial paper
	Payments on borrowings from credit facilities
	Proceeds from borrowings on credit facilities
	Payments on long-term borrowings and debt extinguishment costs
	Proceeds from long-term borrowings, net of debt issuance costs
	Free cash flow to equity (FCFE)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

The financial data for the period from December 31, 2018, to December 31, 2022, reveals certain patterns and fluctuations in cash-related activities.

Cash Provided by Operating Activities:: The cash generated from operating activities exhibited a significant increase from 310 million US dollars in 2018 to a peak of 1,836 million US dollars in 2019. Following this peak, there was a decline to 1,508 million US dollars in 2020, followed by a recovery to 1,870 million US dollars in 2021. The figure then fell again to 1,526 million US dollars in 2022. These fluctuations suggest variability in the company's ability to generate operating cash flow, with 2019 and 2021 being the strongest years within the period observed.
Free Cash Flow to Equity (FCFE):: The FCFE showed a substantial increase from 1,413 million US dollars in 2018 to a high of 4,176 million US dollars in 2019, indicating a significant improvement in the cash available to shareholders after accounting for capital expenditures and debt repayments. However, there was a sharp drop to 145 million US dollars in 2020. The FCFE partially recovered to 1,330 million US dollars in 2021 but then declined again to 785 million US dollars in 2022. This pattern indicates volatility in the company's free cash flows available to equity holders, with a notably strong year in 2019 and weaker performance in subsequent years.

Overall, both cash provided by operating activities and free cash flow to equity experienced notable volatility during the five-year period. The years 2019 and 2021 represented peak levels for operating cash generation, while free cash flow availability to equity holders reached its highest point in 2019 but showed a declining trend thereafter. These variations could reflect changes in operational efficiency, investment activities, or financial strategies impacting liquidity and shareholder returns over time.

Download chart

Price to FCFE Ratio, Current

Boston Scientific Corp., current P/FCFE calculation, comparison to benchmarks

No. shares of common stock outstanding
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in millions)
FCFE per share
Current share price (P)
Valuation Ratio
P/FCFE
Benchmarks
P/FCFE, Competitors¹
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.
P/FCFE, Sector
Health Care Equipment & Services
P/FCFE, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31).

¹ Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Price to FCFE Ratio, Historical

Boston Scientific Corp., historical P/FCFE calculation, comparison to benchmarks

		Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Free cash flow to equity (FCFE) (in millions)²
	FCFE per share³
	Share price^1, 4
	Valuation Ratio
	P/FCFE⁵
	Benchmarks
	P/FCFE, Competitors⁶
	Abbott Laboratories
	Elevance Health Inc.
	Intuitive Surgical Inc.
	Medtronic PLC
	UnitedHealth Group Inc.
	P/FCFE, Sector
	Health Care Equipment & Services
	P/FCFE, Industry
	Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ Data adjusted for splits and stock dividends.

² See details »

³ 2022 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =

⁴ Closing price as at the filing date of Boston Scientific Corp. Annual Report.

⁵ 2022 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =

⁶ Click competitor name to see calculations.

Share Price Trends: The share price shows a generally increasing trend over the five-year period. It started at $39.86 at the end of 2018 and remained nearly stable in 2019 at $39.91. A slight decrease occurred in 2020 with the price falling to $38.75. Subsequent years saw a recovery and growth, reaching $43.71 in 2021 and further increasing to $47.18 in 2022, representing an overall positive momentum in market valuation.
Free Cash Flow to Equity (FCFE) per Share: The FCFE per share experienced significant volatility during the period. It began at $1.02 in 2018 and increased notably to $2.99 in 2019, indicating improved cash flow generation. However, there was a sharp decline in 2020 to only $0.10, suggesting potential disruptions or increased capital expenditures impacting free cash flow. The value partially recovered in 2021 to $0.93 but declined again to $0.55 in 2022, pointing to continued variability and possible challenges in maintaining consistent free cash flow levels.
Price to FCFE (P/FCFE) Ratio: The P/FCFE ratio demonstrated considerable fluctuations reflecting the changes in FCFE per share and share price dynamics. In 2018, the ratio was relatively high at 39.1, then declined sharply to 13.34 in 2019, corresponding with the rise in FCFE per share. In 2020, the ratio surged dramatically to 378.73 due to the precipitous drop in FCFE per share despite a stable share price, indicating potential overvaluation relative to free cash flow. The ratio decreased to 46.89 in 2021 as FCFE rebounded, but increased again to 86.23 in 2022 amid declining FCFE per share and rising share prices, suggesting ongoing volatility and mixed market sentiment regarding cash flow sustainability.